After 2 weeks of treatment, most subjects’ IGA grade changed from “moderate” to “mild.”1,b
Results 1 of 3: Improvement in psoriatic plaque on the extensor forearm over 28 days of treatment
Results 2 of 3: Improvement in psoriatic plaque on the shin over 28 days of treatment
Results 3 of 3: Improvement in psoriatic plaque on the knee over 28 days of treatment
aStandard photographs of lesions on the knee, extensor forearm, and shin were taken at Days 1, 8, 14, and 29. Results may vary. bThe average decrease in Investigator’s Global Assessment (IGA) of approximately one grade from baseline to Day 14.
Patients reported significant improvements in Treatment Satisfaction Questionnaire for Medication (TSQM) by Day 14 in an open-label study (n=45)1,c,d
cResults of an open-label, multicenter study (n=45). Co-primary endpoint for study included change in TSQM from baseline at Day 14.
dEvaluated using TSQM version 2.0, an 11-item instrument measuring 4 dimensions of treatment satisfaction (Effectiveness, Side Effects, Convenience, and Overall Satisfaction) that yields a total score ranging from 0 (extremely dissatisfied) to 100 (extremely satisfied).2
Results show a continued improvement of DLQI scores over 4 weeks of treatment in an open-label study (n=45)e
Improved QoL Ratings Reflected by Reduction in DLQI Scores
eResults of an open-label, multicenter study (n=45). The Dermatology Life Quality Index (DLQI) is a validated, 10-item questionnaire that assesses dermatology-specific quality of life (QoL),3,4 and yields a total score of 0 (best QoL) to 30 (worst QoL).5 Thus, a decrease in DLQI score indicates improvement.
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray.
Please refer to Full Prescribing Information.
SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.
To report ADVERSE EVENTS, call 1-800-399-2561 or AE@encorederm.com, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.